Who
Thomas A. Fitzgerald
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, TransCode Therapeutics.
In numbers
- Trades disclosed
- 9
- Buys
- 2
- Sells
- 0
- Bought
- $40K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Feb 2022
- Last trade
- 9 Sep 2026
- Last filed
- 11 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Sep 2026filed 11 Sep 2026 | RNAZ TransCode Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —185,000 at $0.00 | filing |
| 9 Sep 2026filed 11 Sep 2026 | RNAZ TransCode Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —185,000 at $0.00 | filing |
| 14 Jun 2024filed 18 Jun 2024 | RNAZ TransCode Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —650,000 at $0.00 | filing |
| 28 Sep 2023filed 2 Oct 2023 | RNAZ TransCode TherapeuticsBiotechnology | SEC FORM 4 Bought | $25K49,350 at $0.51 | filing |
| 19 May 2023filed 19 May 2023 | RNAZ TransCode Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 12 Dec 2022filed 14 Dec 2022 | RNAZ TransCode Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 16 Jun 2022filed 17 Jun 2022 | RNAZ TransCode TherapeuticsBiotechnology | SEC FORM 4 Bought | $15K12,000 at $1.27 | filing |
| 1 Mar 2022filed 2 Mar 2022 | RNAZ TransCode Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —52,000 at $0.00 | filing |
| 1 Feb 2022filed 3 Feb 2022 | RNAZ TransCode Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.